Development of a perfusion chamber assay to study in real time the kinetics of thrombosis and the antithrombotic characteristics of antiplatelet drugs

Table 2 Characteristics of the thrombotic profiles generated upon in vitro addition of saline, eptifibatide and 2-MeSAMP (2MeS.)

Parameters		(Saline)	2-MeS. (10 μM)	2-MeS. (100 μM)	Aspirin (asa)	2-MeS. (10 μM) + asa	2-MeS. (100 μM) + asa	Eptifibatide (2.4 μM)
Maximum Peak (pixels/μm²)	Mean Median	596 ± 65 693	309 ± 54 * 318	160 ± 50 ** 109	455 ± 61 423	218 ± 530 **,† 189	127 ± 33 ***, †† 103	63.5 ± 12 *** 53
Time to the peak (sec)	Mean Median	240 ± 0.1 240	216 ± 16 240	197 ± 22 * 231	239 + 0.5 239	214 ± 12 228	204.6 ± 16 *,†† 233	234.4 ± 10 240
Slope before the peak	Mean Median	3.2 ± 0.3 3.1	1.96 ± 0.3 * 1.87	1 ± 0.24 ** 0.94	2.47 + 0.37 2.14	1.33 ± 0.4 **,† 1.13	0.77 ± 0.2 ***,†† 0.43	0.34 ± 0.07 *** 0.3
Slope after the peak	Mean Median	0/7^#	2/7^# −0.3 ± 0.1	4/7^# −0.5 ± 0.24	1/7^# −0.15	4/7^# −1.4 ± 0.66	3/7^# −0.07 ± .02	4/7^# −0.13 ± 0.05

Compounds were added to untreated or aspirinated blood samples (individuals on a 325 mg/d aspirin dose for 3 days). *, **, *** ; P < 0.05, P < 0.01, P < 0.0001 vs baseline, respectively. †, ††, P < 0.05, P < 0.01 vs aspirin (n = 7). ^# indicates number of curves with reversal.

ISSN: 1477-9560